Navigation Links
Neuralstem chief scientific officer to take part in World Stem Cell Summit plenary session
Date:10/1/2010

Neuralstem, Inc. (NYSE Amex: CUR) announced that the Chairman of its Board of Directors and Chief Scientific Officer, Dr. Karl Johe, PhD, will take part in a plenary discussion entitled, Current and Future Clinical Trials and Stem Cell Therapies, at the World Stem Cell Summit on October 5, in Detroit, MI (http://www.worldstemcellsummit.com/summit-agenda). Dr. Johe is the creator of Neuralstems neural stem cell technology.

The panel will be moderated by Dr. Eva Feldman, PhD, MD, Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System, and includes as well Dr. Jonathan Glass, MD, Professor of Neurology & Director Emory ALS Center Emory University, and Dr. Nicholas Boulis, MD, Assistant Professor Neurosurgery Emory University.

Neuralstem is currently sponsoring a Phase I trial of its spinal cord stem cells in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrigs disease) at the ALS Center at Emory University, in Atlanta, GA. Dr. Feldman is the Principal Investigator, Dr. Glass is the Site Principal Investigator and Dr. Boulis is the Co-Investigator and Neurosurgeon.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a Phase I safety clinical trial for Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. In addition to ALS, the company is targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington's disease. The company has also submitted an IND application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Through its proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company plans to initiate clinical trials to treat Alzheimer's disease and major depression with its lead compound, as well as pursue additional indications, including traumatic brain injury, posttraumatic stress syndrome, stroke and schizophrenia.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Related medicine news :

1. Neuralstem stem cells survive and differentiate into neurons in rats with stroke
2. Neuralstem files FDA application for first chronic spinal cord injury stem cell trial
3. Neuralstem updates clinical trial progress
4. National Institute of General Medical Sciences chief wins prestigious public service award
5. FDA Chief Says More Egg Recalls Possible
6. Spectrum Surgical Instruments Appoints President, Chief Operating Officer
7. DKI Direct Appoints Greg Lewis as Chief Marketing Officer
8. BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role
9. Steri -7 Appoints BioNeutral Group Inc. Chief Scientist Dr. Andy Kielbania for Expanded Role
10. Former NIH Chief Joins Children's National Medical Center
11. Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of Alex Leaf Distinguished Scientist Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: